Hepatic toxicity of antiviral agents

Drug-Induced Liver Disease, Second Edition

Volumn , Issue , 2007, Pages 567-591

  Spengler, Ulrich ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 46349099842     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (219)

1. Den Brinker M, Wit FW, Wertheim-van Dillen PM, et al. Hepatitis B and C virus con-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000; 14:2895-902.
2. Sulkowski MS, Thomas DL, Chaisson RE, Moore RDl. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283:74-80.
3. Ensoli F, Sirianni MC. HIV/HCV co-infection: clinical and therapeutic challenges. AIDS 2002; 16:1419-20.
4. Bruno R, Sacchi P, Puoti M, Soriano V, Filice G. HCV chroni hepatitis in patients with HIV: clinical management issues. Am J Gastroenterol 2002; 97:1598-606.
5. Benhamou Y. Antiretroviral therapy and HIV/hepatitis B virus coinfection. Clin Infect Dis 2004; 38(Suppl. 2):S98-103.
6. Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, Snydman DR. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32:492-7.
7. Wit FWNM, Weverling GJ, Weel J, Jurriaans S, Lange JMA. Incidence and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 2002; 186:25-31.
8. Puoti M, Torti C, Ripamonti D, Castelli F, Zaltron S, Zanini B, Spinetti A, Putzolu V, Casari S, Tomasoni L, et al. Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcome. J Acquir Immune Defic Syndr 2003; 32:259-67.
9. Stern JO, Robinson PA, Love J, Lanes S, Imperiale MS, Mayers DL. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr 2003; 34:S21-33.
10. Bissuel F, Bruneel F, Habersetzer F, et al. Fulminant hepatitis with severe lactate acidosis in HIVinfected patients on didanosine therapy. J Intern Med 1994; 235:367-71.
11. Anonymus. Report on an international consensus meeting. Criteria of drug-induced liver disorders. J Hepatol 1990; 11:272-6.
12. AIDS Clinical Trials Group. Table of grading severity of adult adverse experiences. Rockville MD:Division of AIDS, National Institute of Allergy and Infectious Diseases, 1996.
13. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevaripine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002; 35:182-9.
14. Nuñez M, Lana R, Mendoza JL, Martin-Carbonero L, Soriano V. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 27:426-31.
15. Palmon K, Koo BCA, Shoultz DA, Dieterich DT. Lack of hepatotoxicity associated with nonnucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2002; 29:340-5.
16. Bonfanti P, Landonio S, Ricci E, et al. Risk factors for hepatotoxicity in HIV-infected patients treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 167(316):8 (Letter).
17. Martinez E, Blanco JL, Arnaiz JA, et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001; 15:1261-8.
18. Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK. Panel on Clinical Practices for the Treatment of HIV. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents:recommendations of the Panel on Clinical Practices for Treatment of HIV. MMWR Morb Mort Wkly Rep 2002; 51(RR-07):1-64.
19. Madge S, Mocroft A, Wilson D, et al. Participation in clinical studies among patients infected with HIV-1 in a single treatment centre over 12 years. HIV Med 2000; 1:212-8.
20. Gifford AL, Cunningham WE, Heslin KC, et al. Participation in research and access to experimental treatments by HIV-infected patients. N Engl J Med 2002; 346:1373-82.
21. Gisolf HE, Dreezen C, Danner SA, Weel JL, Weverling GJ. Prometheus Study Group. Risk factors for hepatotoxicity in HIV infected patients receiving ritonavir and saquinavir with or without stavudine. Clin Infect Dis 2000; 31:1234-9.
22. Stawzewski S, Keiser P, Montaner J, Raffi F, Gathe J, Brotas V, Hicks C, Hammer SM, Cooper D, Johnson M, et al. Abacavir-lamivudine-zidovudine vs. indinavir-lamivudine-zidovudine in antiretroviral- naive HIV-infected adults. JAMA 2001; 285:1155-63.
23. Sanne I. Severe liver toxicity in patients receiving two nucleoside analogues and a non-nucleoside reverse transcriptase inhibitor. AIDS 2000; 14(Suppl. 4):S12 (Abstract PL9.3).
24. Fung SK, Andreone P, Han SH, et al. Adefovir resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J Hepatol 2005; 43:937-43.
25. Kakuda TN. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 2000; 22:685-708.
26. Lewis W, Dalakas M. Mitochondrial toxicity of antiviral drugs. Nat Med 1995; 1:417-22.
27. Lewis W, Day BJ, Copeland WC. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat Rev Drug Discov 2003; 2:812-22.
28. Walker UA, Setzer B, Venhoff N. Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse transcriptase inhibitors. AIDS 2002; 16:2165-73.
29. Lim SE, Copeland WC. Differential incorporation and removal of antiviral deoxynucleotides by human polymerase-γ. J Biol Chem 2001; 276:23616-23.
30. Johnson AA, Ray AS, Hanes J, Suo Z, Colacino JM, Andersen KS, Johnson KA. Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. J Biol Chem 2001; 276:40847-57.
31. Walker UA, Bäuerle J, Laguno M, et al. Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine or zalcitabine. Hepatology 2004; 39:311-7.
32. Hart GJ, Orr DC, Penn CR, Figueiredo HT, Gray NM, Boehme RE, Cameron JM. Effects of (-)-2'- deoxy-3'-thiacytidine (3TC) 5'-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma. Antimicrob Agents Chemother 1992; 36:1688-94.
33. Birkus G, Hitchcock MJM, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2002; 46:716-23.
34. Birkus G, Gibbs CS, Cihlar T. Comparative effects of adefovir and selected nucleoside inhibitors of hepatitis B virus DNA polymerase on mitochondrial DNA in liver and skeletal muscle cells. J Viral Hepat 2003; 10:50-4.
35. Cihlar T, Birkus G, Greenwalt DE, Hitchcock MJ. Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors. Antiviral Res 2002; 54:37-45.
36. Sanchez-Conde M, Mendoza C, Jimenez-Nacher I, Barreiro P, Gonzalez-Lahoz J, Soriano V. Reductions in stavudine dose might ameliorate mitochondrial-associated complications without compromising antiviral activity. HIV Clin Trials 2005; 6:197-202.
37. Bäuerle J, Laguno M, Mauss S, et al. Mitochondrial DNA depletion in liver tissue of patients infected with hepatitis C virus: contributing effect of HIV infection? HIV Med 2005; 6:135-9.
38. Harvie P, Omar RF, Duserre N, et al. Ribavirin potentiates the efficacy and toxicity of 2',3'-dideoxyinosine in the murine acquired immunodeficiency syndrome model. J Pharmacol Exp Ther 1996; 279:1009-17.
39. Becher F, Pruvost AG, Schlemmer DD, et al. Significant levels of intracellular stavudine triphosphate are found in HIV-infected zidovudine-treated patients. AIDS 2003; 17:555-61.
40. Bonora S, Boffito M, D’Avolio A, et al. Detection of stavudine concentrations in plasma of HIVinfected patients taking zidovudine. AIDS 2004; 18:577-8.
41. Barile M, Valenti D, Hobbs GA, et al. Mechanism of toxicity of 3'-azido-3‘deoxythymidine. Its interaction with adenylate kinase. Biochem Pharmacol 1994; 48:1405-12.
42. Barile M, Valenti D, Passarella S, Quagliariello E. 3'-azido-3' deoxythymidine uptake into isolated rat liver mitochondria and impairment of ADP/ATP translocator. Biochem Pharmacol 1997; 53:913-20.
43. Valenti D, Barile M, Passarella S. AZT inhibition of the ADP/ATP antiport in isolated rat heart mitochondria. Int J Mol Med 2000; 6:93-6.
44. Valenti D, Barile M, Quagliariello E, Passarella S. Inhibition of nucleoside diphosphate kinase in rat liver mitochondria by added 3'-azido-3'-deoxythymidine. FEBS Lett 1999; 444:291-5.
45. Hall ET, Yan JP, Melancon P, Kuchta RD. 3'-azido-3'-deoxythymidine potently inhibits protein glycosylation. A novel mechanism for AZT toxicity. J Biol Chem 1994; 269:14355-85.
46. Weidner DA, Sommadossi JP. 3'-azido-3'-deoxythymidine inhibits globin gene transcription in butyric acid-induced K562 human leukemia cells. Mol Pharmacol 1990; 38:797-804.
47. Hobbs GA, Keilbaugh SA, Rief PM, Simpson MV. Cellular targets of 3'-azido-3'-deoxythymidine:an early (non-delayed) effect on oxidative phosphorylation. Biochem Pharmacol 1995; 50:381-90.
48. Hayakawa M, Ogawa T, Sugiyama S, Tanaka M, Ozawa T. Massive conversion of guanosine to 8-hydroxy-guanosine in mouse liver mitochondrial DNA by administration of azidothymidine. Biochem Biophys Res Commun 1991; 176:87-93.
49. De la Asuncion JG, Del Olmo ML, Sastre J, Pallardo FV, Vina J. Zidovudine (AZT) causes an oxidation of mitochondrial DNA in mouse liver. Hepatology 1999; 25:985-7.
50. Löffler M, Jöckel J, Schuster G, Becker C. Dihydroorotat-ubiquinone oxidoreductase links mitochondria in the biosynthesis of pyrimidine nucleotides. Mol Cell Biochem 1997; 174:125-9.
51. Fromenty B, Berson A, Pessayre D. Microvesicular steatosis and steatohepatitis: role of mitochondrial dysfunction and lipid peroxidation. J Hepatol 1997; 26(Suppl. 1):13-22.
52. Day CP, James OF. Hepatic steatosis: innocent bystander or guilty party? Hepatology 1998; 27:1463-6.
53. Pessayre D, Mansouri A, Haouzi D, Fromenty B. Hepatotoxicity due to mitochondrial dysfunction. Cell Biol Toxicol 1999; 15:367-73.
54. Pessayre D, Berson A, Fromenty B, Mansouri A. Mitochondria in steatohepatitis. Semin Liver Dis 2001; 21:57-69.
55. Tsukamoto H, Kim CW, Luo ZZ, Horn W, Su LC, Brittenham GM. Role of lipid peroxidation in in vivo and in vitro models of liver fibrogenesis. Gastroenterology 1993; 104:A101.
56. Susin SA, Zamzani N, Kroemer G. Mitochondria as regulators of apoptosis: doubt no more. Biochim Biophys Acta 1998; 1366:151-65.
57. Pessayre D, Haouzi D, Fau D, Robin MA, Moreau A, Neumann M. Hepatocyte apoptosis triggered by natural substances. In: Cameron RG, Feuer G, eds. Apoptosis and Its Modulation by Drugs. Handbook of Experimental Pharmacology, Vol. 142. Heidelberg: Springer, 2000:59-108.
58. Carr A, Morey A, Mallon P, Williams D, Thorburn DR. Fatal portal hypertension, liver failure, and mitochondrial dysfunction after HIV-1 nucleoside analogue-induced hepatitis and lactic acidaemia. Lancet 2001; 357:1412-4.
59. Clark SJ, Creigthon S, Portmann B, Taylor C, Wendon JA, Cramp ME. Acute liver failure associated with antiretroviral treatment for HIV: a report of six cases. J Hepatol 2002; 36:295-301.
60. Moyle G. Toxicity of antiretroviral nucleoside and nucleotide analogues. Drug Saf 2000; 23:467-81.
61. Hass S, Rockstroh JK, Spengler U, Fischer HP. Nucleoside induced hepatopathy in HIV patients. Diagnostic value of liver biopsy assessment. Der Pathologe 2004; 25:406-11.
62. Saint-Marc T, Touraine JL. The effects of discontinuing stavudine therapy on clinical and metabolic abnormalities in patients suffering from lipodystrophy. AIDS 1999; 13:2188-9.
63. Carr A, Miller J, Law M, Cooper DA. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitorrelated lipodystrophy syndrome. AIDS 2000; 14:F25-32.
64. Arnaudo E, Dalakas M, Shanske S, Moraes CT, DiMauro S, Schon EA. Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet 1991; 337:508-10.
65. Simpson DM, Tagliati M. Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection. J Acquir Immune Defic Syndr 1995; 9:153-61.
66. Maxson CJ, Greenfield SM, Turner JL. Acute pancreatitis as a common complication of 2',3'- dideoxyinosine therapy in the acquired immunodeficiency syndrome. Am J Gastroenterol 1992; 87:708-13.
67. Ray AS, Olson L, Fridland A. Role of purine nucleoside phosphorylase in interactions between 2',3'- dideoxyinosine and allopurinol, ganciclovir, or tenofovir. Antimicrob Agents Chemother 2004; 48:1089-95.
68. Pollard RB, Robinson P, Dransfield K. Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin Ther 1998; 20:1071-92.
69. Lee W. Drug-induced hepatotoxicity. N Engl J Med 2003; 349:474-85.
70. Carr A, Cooper DA. Pathogenesis and management of HIV-associated drug hypersensitivity. In: Volberding P, Jacobson MA, eds. AIDS Clinical Review 1995/96. New York: Marcel Dekker, 1996:65-97.
71. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLADQ3 and hypersensitivity to HIV-1 reverse transcriptase inhibitor abacavir. Lancet 2002; 359:727-32.
72. Heatherington S, Hughes AR, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 2002; 359:1121-2.
73. Martin AM, Nolan D, Gaudieri S, et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp 70-Hom variant. Proc Natl Acad Sci USA 2004; 101:4180-5.
74. Hughes DA, Vilar FJ, Ward CC, Alfirevic A, Park BK, Pirmohamed M. Cost-effectiveness analysis of HLA-B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics 2004; 14:335-42.
75. Phillips EJ, Sullivan JR, Knowles SR, Shear NH. Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir. AIDS 2002; 15:2223-5.
76. Martin AM, Nolan D, James I, et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4-T-cell counts. AIDS 2005; 19:97-9.
77. Easterbrook PJ, Waters A, Murad S, et al. Epidemiological risk factors for hypersensitivity reactions to abacavir. HIV Med 2003; 4:321-4.
78. King D, Tomkins S, Waters A, et al. Intracellular cytokines may model immunoregulation of abacavir hypersensitivity in HIV-infected subjects. J Allergy Clin Immunol 2005; 115:1081-7.
79. Phillips E, Wong GA, Kaul R, et al. Clinical and immunogenetic correlates of abacavir hypersensitivity. AIDS 2005; 19:979-87.
80. De Maat MMR, ter Hein R, van Gorp ECM, Mulder JW, Mairuhu ATA, Beijnen JH. Case series of acute hepatitis in a non-selected group of HIV-infected patients on vevirapine-containing antiretroviral treatment. AIDS 2003; 17:2209-14.
81. Spengler U, Lichterfeld M, Rockstroh H. Antiretroviral drug toxicity-a challenge for the hepatologist? J Hepatol 2002; 36:283-94.
82. Wooltorton E. HIV drug nevirapine (Viramune): risk of severe hepatotoxicity. CMAJ 2004; 170:1091.
83. Zucker SD, Quin X, Rouster SD, Yu F, Green RM, Keshavan P. Mechanism of indinavir-induced hyperbilirubinemia. Proc Natl Acad Sci USA 2001; 98:12671-6.
84. FDA notifications. Reyataz is approved for HIV treatment. AIDS Alert 2003; 18:119-20.
85. Busti AJ, Hall RG, Margolis DM. Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy 2004; 24(12):1732-47.
86. Robinson BS, Riccardi KA, Gong YF, et al. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob Agents Chemother 2000; 44:2093-9.
87. Raijmakers MT, Jansen PL, Steegers EA, Peters WH. Association of human liver bilirubin UDPglucuronosyltransferase activity with a polymorphism in the promoter region of the UGT1A1 gene. J Hepatol 2000; 33:348-51.
88. Rotger M, Taffe P, Bleiber G, et al. Gilber syndrome and the development of antiretroviral therapyassociated hyperbilirubinemia. J Infect Dis 2005; 192:1381-6.
89. Sulkowski MS, Mehta SH, Tobenson M, Afdahl NH, Mirel L, Moore RD, Thomas DL. Hepatic steatosis and antiretroviral drug use among adults coninfected with HIV and hepatitis C virus. AIDS 2005; 19:585-92.
90. Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiereo G, Day CP. Steatosis and hepatitis C virus:mechanisms and significance for hepatitis and extrahepatic disease. Gastroenterology 2004; 126:586-97.
91. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33:1358-64.
92. Patton HM, Patel K, Behling C, et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 2004; 40:484-90.
93. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353:2093-9.
94. Riddle TM, Kuhel DG, Woollett LA, Fichtenbaum CJ, Hui DY. HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. J Biol Chem 2001; 276:37514-9.
95. Hashimoto KI, Tsunoda R, Okamoto M, Shigeta S, Baba M. Stavudine selectively induces apoptosis in HIV type 1-infected cells. AIDS Res Hum Retroviruses 1997; 13:193-9.
96. Strahl C, Blackburn EH. Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines. Mol Cell Biol 1996; 16:53-65.
97. Cattelan AM, Erne E, Salatino A, Trevenzoli M, Carretta G, Meneghetti F, Cadrobbi P. Severe hepatic failure related to nevirapine treatment. Clin Infect Dis 1999; 29:455-6.
98. Peters M. Mechanisms of action of interferons. Semin Liver Dis 1989; 9:235-9.
99. McDonald JA, Caruso L, Karayannis P, Scully LJ, Harris JR, Forster GE, Thomas HC. Diminished responsiveness of male homosexual chronic hepatitis B virus carriers with HTLV-III antibodies to recombinant alpha-interferon. Hepatology 1987; 4:719-23.
100. Scully LJ, Brown D, Lloyd C, Shein R, Thomas HC. Immunological studies before and during interferon therapy in chronic HBV infection. Identification of factors predicting response. Hepatology 1990; 12:1111-7.
101. Rockstroh JK, Spengler U. HIV and HCV coinfection. Lancet Infect Dis 2004; 4:437-44.
102. Quesada JR, Tapaz M, Rios A, Kurzrock R, Gutterman JU. Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol 1986; 4:234-43.
103. Spiegel RJ. The alpha interferons: clinical overview. Semin Oncol 1987; 14(Suppl. 2):1-12.
104. Janssen HL, Brouwer JT, Nevens F, Sanchez-Tapias JM, Craxi A, Hadziyannis S. Fatal hepatic decompensation associated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP). BMJ 1993; 306:107-8.
105. Silva MO, Reddy KR, Jeffers LJ, Hill M, Schiff ER. Interferon-induced chronic active hepatitis? Gastroenterology 1991; 101:840-2.
106. Ruiz-Moreno M, Rua JM, Carreño V, Quiroga JA, Manns M, Meyer zum Büschenfelde KH. Autoimmune chronic hepatitis type 2 manifested during interferon therapy in children. J Hepatol 1991; 12:265-6.
107. Papo T, Marcellin P, Bernuau J, Durand F, Poynard T, Benhamou JP. Autoimmune hepatitis exacerbated by alpha-interferon. Ann Intern Med 1992; 116:51-3.
108. Shindo M, DiBisceglie AM, Hoofnagle JH. Acute exacerbation of liver disease during interferon alfa therapy for chronic hepatitis C. Gastroenterology 1992; 102:1406-8.
109. Garcia-Buey L, Garcia-Monzon C, Rodriguez S. Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis. Gastroenterology 1995; 108:1770-7.
110. Cianciara J, Laskus T. Development of transient autoimmune hepatitis during interferon treatment of chronic hepatitis B. Dig Dis Sci 1995; 40:1842-4.
111. Bellary S, Schiano T, Hartman G, Black M. Chronic hepatitis with combined features of autoimmune chronic hepatitis and chronic hepatitis C: favorable response to prednisone and azathioprine. Ann Intern Med 1995; 123:32-4.
112. Lorke J, Erhardt A, Häussinger D. Induction of autoimmune hepatitis by pegylated interferon alfa-2b in chronic hepatitis C. Clin Gastroenterol Hepatol 2004; 2:XX.
113. Sezaki H, Arase Y, Tsubota A, et al. Type C-chronic hepatitis patients who had autoimmune phenomenon and developed jaundice during interferon therapy. J Gastroenterol 2003; 38:493-500.
114. Yamamoto AM, Cresteil D, Homberg JC, Alvarez FI. Characterization of anti-liver kidney microsome antibody (anti-LKM1) from hepatitis C virus-positive and -negative sera. Gastroenterology 1993; 104:1762-7.
115. Muratori L, Lenzi M, Ma Y, Cataleta M, Mieli-Vergani G, Vergani D, Bianchi FB. Heterogeneity of liver/kidney microsomal antibody type 1 in autoimmune hepatitis and hepatitis C virus related liver disease. Gut 1995; 37:406-12.
116. Muratori L, Lenzi M, Cataleta M, et al. Interferon therapy in liver/kidney microsomal antibody type 1-positive patients with chronic hepatitis C. J Hepatol 1994; 21:199-203.
117. Gschwantler M, Schrutka-Kolbl C, Weiss W. Acute exacerbation of anti-liver cytosol antibodypositive autoimmune chronic hepatitis by alpha-interferon. Am J Gastroenterol 1995; 90:2239-40.
118. Saves M, Vandentorren S, Daucourt V, et al. Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996-1998. Groupe d ‘Epidemiologie Clinique de Sida en Aquitaine (GECSA). AIDS 1999; 17:F115-21.
119. Fortgang IS, Belitsos PC, Chaisson RE, Moore RD. Hepatomegaly and steatosis in HIVinfected patients receiving nucleoside analog antiretroviral therapy. Am J Gastroenterol 1995; 90:1433-6.
120. Mokrzycki MH, Harris C, May H, Laut J, Palmisano J. Lactic acidosis associated with stavudine administration: a report of five cases. Clin Infect Dis 2000; 30:198-200.
121. Olano JP, Borucki MJ, Wen JW, Haque AK. Massive hepatic steatosis and lactic acidosis in a patient with AIDS who was receiving zidovudine. Clin Infect Dis 1995; 21:973-6.
122. Reisler R, Liou S, Servoss J, Robbins G, Theodore D, Murphy R, Chung R. Incidence of hepatotoxicity and mortality in 21 adult antiretroviral treatment trials (Abstract 43). 1st IAS Conference on HIV Pathogenesis and Treatment. July 2001. Argentina: Buenos Aires.
123. Ormseth EJ, Holtzmuller KC, Goodman ZD, Colonna JO, Batty DS, Sjogren MH. Hepatic decompensation associated with lamivudine: a case report and review of lamivudine-induced hepatotoxicity. Am J Gastroenterol 2001; 96:1619-22.
124. ter Hofstede HJ, de Marie S, Foudraine NA, Danner SA, Brinkman K. Clinical features and risk factors of lactic acidosis following long-term antiretroviral therapy: 4 fatal cases. Int J STD AIDS 2000; 11:611-6.
125. Lai KK, Gang DL, Zawacki JK, Cooley TP. Fulminant hepatic failure associated with 2',3'-dideoxyinosine (ddI). Ann Intern Med 1991; 115:283-4.
126. Lafeuillade A, Hittinger G, Chadapaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 2001; 357:280-1.
127. European Agency for the Evaluation of Medicinal Products (EMEA). Reports of lactic acidosis in pregnant women treated with Zerit and Videx. Press release January 31st, 2001.
128. Ellozy S, Massen R, Chao L, Divino CM. Antiretroviral-induced hepatic steatosis and lactic acidosis:case report and review of the literature. Am Surg 2001; 67:680-3.
129. Lonergan JT, Barber RE, Mathews WC. Safety and efficacy of switching to alternative nucleoside analogues following symptomatic hyperlactatemia and lactic acidosis. AIDS 2003; 17:2495-9.
130. Fouty B, Frerman F, Reves R. Riboflavin to treat nucleoside analogue-induced lactic acidosis. Lancet 1998; 352:291-2.
131. Schramm C, Wanitschke R, Galle PR. Thiamine for the treatment of nucleoside analogue-induced severe lactic acidosis. Eur J Anaesthesiol 1999; 16:733-5.
132. Walker UA, Venhoff N, Koch E, Olschweski M, Schneider J, Setzer B. Uridine abrogates mitochondrial toxicity related to nucleoside analogue reverse transcriptase inhibitors in HepG2 cells. Antivir Ther 2003; 8:463-70.
133. Walker UA, Auclair M, Lebrecht D, Kornprobst M, Capeau J, Caron M. Uridine abrogates the adverse effects of stavudine and zalcitabine on adipose cell functions. Antivir Ther 2004; 9:L21-2.
134. van Groeningen CJ, Leyva A, Kraal I, Peters GJ, Pinedo HM. Clinical and pharmacokinetic studies of prolonged administration of high-dose uridine intended for rescue from 5-FU toxicity. Cancer Treat Rep 1986; 70:745-50.
135. Kelsen DP, Martin D, O’Neil J, et al. Phase I trial of PN401, an oral prodrug of uridine, to prevent toxicity from fluorouracil in patients with advanced cancer. J Clin Oncol 1997; 15:1511-7.
136. Sommadossi JP, Carlisle R, Schinazi RF, Zhou Z. Uridine reverses the toxicity of 3'-azido-3'- deoxythymidine in normal human granulocyte-macrophage progenitor cells in vitro without impairment of antiretroviral activity. Antimicrob Agents Chemother 1988; 32:997-1001.
137. Koch EC, Schneider J, Weiss R, Penning B, Walker UA. Uridine excess does not interfere with the antiretroviral efficacy of nucleoside analogue reverse transcriptase inhibitors. Antivir Ther 2003; 8:485-7.
138. Venhoff N, Zilly M, Lebrecht D, et al. Uridine pharmacokinetics of Mitocnol, a sugarcane extract. AIDS 2005; 19:739-40.
139. Walker UA, Langmann P, Miehle N, Zilly M, Klinker H, Petschner F. Beneficial effects of oral uridine in mitochondrial toxicity. AIDS 2004; 18:1085-6.
140. Boehringer Ingelheim. International Viramune Product Monograph http://hiv.net/link. php?id=121.
141. Cahn P, Johnson M, Nusrat R, Hall D, Robinson P. Hepatic safety with nevirapine and two nucleosides in patients with advanced HIV infection, from a placebo controlled clinical endpoint trail (Abstract PL 8.6). 5th International Congress in HIV infection. October 2000. Glasgow, Scotland.
142. Dieterich DT, Robinson PA, Love J, Stern JO. Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors. Clin Infect Dis 2004; 38(Suppl. 12):S80-9.
143. Lebray P, Benhamou Y, Pol S, Myers R, Poynard T, Di Martino V. NNRTI-related or unrelated hepatotoxicity. Hepatology 2002; 36:513-4 (Letter).
144. Ena J, Amador C, Benito C, Fenoli V, Pasquau F. Risk and determinants of developing severe liver toxicity during therapy with nevirapine- and efavirenz-containing regimens in HIV-infected patients. Int J STD AIDS 2003; 14:776-81.
145. Bonnet F, Lawson-Ayayi S, Thiebaut R, et al. A cohort study of nevirapine tolerance in clinical practice: French Aquitaine Cohort, 1997-1999. Clin Infec Dis 2002; 3:1231-7.
146. Centers for Disease Control and Prevention. Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures-worldwide, 1997-2000. Morb and Mortal Wkly Rep 2001; 49:1153-6.
147. Viramune (nevirapine) important new safety information. February 2004. (www.fda.gov/medwatch/SAFETY/2004/safety04.htm#viramune).
148. EMEA public statement on Viramune (nevirapine) - severe and life-threatening cutaneous and hepatic reactions. (http://hiv.net/link.php?id=120).
149. Johnson S, Chan J, Bennet CL. Hepatotoxicity after prophylaxis with a nevirapine-containing regimen. Ann Intern Med 2002; 347:146-7.
150. Clarke S, Harrington P, Condon C, Kelleher D, Smith OP, Mulcahy F. Late onset hepatitis and prolonged deterioration in hepatic function associated with nevirapine therapy. Int J STD AIDS 2000; 11:336-7.
151. Arribas JR, Ibanez C, Ruiz-Antoran B, et al. Acute hepatitis in HIV-infected patients during ritonavir treatment. AIDS 1998; 12:1722-4.
152. Matsuda J, Gohchi K. Severe hepatitis in patients with AIDS and haemophilia B treated with indinavir. Lancet 1997; 350:364.
153. Brau N, Leaf HL, Wieczorek RL, Margolis DM. Severe hepatitis in three AIDS patients treated with indinavir. Lancet 1997; 349:924-5.
154. Saves M, Raffi F, Clevenbergh P, et al. Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. The APROCO Study Group. Antimicrob Agents Chemother 2000; 44:3451-5.
155. Cooper CL, Pabrhakar MA, Angel JB. Hepatoxicity associated with antiretroviral therapy containing dual versus single protease inhibitors in individuals coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis 2002; 34:1259-63.
156. Aceti A, Pasquazzi C, Zechini B, De Bac C. Hepatoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection. J Acquir Immune Defic Syndr 2002; 29:41-8.
157. Sulkowski MS, Mehta SH, Chaisson RE, Thomas DL, Moore RD. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with and without concurrent ritonavir. AIDS 2004; 18:2277-84.
158. Gonzalez-Requena D, Nuñez M, Jimenez-Nacher I, Gonzalez-Lahoz J, Soriano V. Liver toxicity of lopinavir containing regimens in HIV-infected patients with and without hepatitis C co-infection. AIDS Res Hum Retrovirus 2004; 20:698-700.
159. Bonfanti P, Ricci E, Penco G, et al. Low incidence of hepatotoxicity in a cohort of HIV patients treated with lopinavir/ritonavir. AIDS 2005; 19:1433-4.
160. Sulkowski MS. Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors. Clin Infect Dis 2004; 38:S90-7.
161. Almond LM, Boffito M, Hoggard PG, et al. The relationship between nevirapine plasma concentrations and abnormal liver function tests. AIDS Res Hum Retrovirus 2004; 20:716-22.
162. Arribas J, Pulido F, Peng J, et al. Evaluation of multiple-dose pharmacokinetics of lopinavir/ritonavir (LPV/r) in HIV and HCV co-infected patients with mild or moderate hepatic insufficiency. 9th European AIDS Conference Warsaw 2003; Abstract #F2/6.
163. Picard O, Rosmorduc O, Cabane J. Hepatotoxicity associated with ritonavir. Ann Intern Med 1998; 129:670-1.
164. Malaty LI, Kuper JJ. Drug interactions of HIV protease inhibitors. Drug Saf 1999; 20:147-69.
165. Dieterich D, Fischl M, Rimland D, Sepulveda G. The safety and efficacy of protease inhibitors in HCV co-infected patients. 9th CROI, Seattle 2002; Abstract 663-M.
166. Pedneault L, Brothers C, Pagano G, Tymkewycz P, Yeo J, Millard J, Fetter A. Safety profile of amprenavir in the treatment of adult and pediatric patients with HIV infection. Clin Ther 2000; 22:1378-94.
167. Pierone G, Drulak M, Arasteh K, et al. A long-term open-label rollover trial assessing the safety and tolerability of combination tipranavir and ritonavir (TPV/r) us in HIV-1-infected patients. 3rd IAS Conference Rio de Janeiro 2005. (WePe6.2C05).
168. Kemmer N, Molina C, Fuchs J, Miskovsky E, Asmuth D, Borucki S, Weinman S. A distinctive histologic pattern of liver injury in HIV-positive patients on HAART: a possible hepatotoxic effect of protease inhibitors (Abstract 431). Annual Meeting of the American Association for the Study of the Liver. November 2000. Dallas, U.S.A.
169. Cox SR, Ferrey JJ, Batts DH, et al. Delavirdine and marketed protease inhibitors: pharmakokinetic interaction studies in healthy volunteers (Abstract 372). 4th Conference on Retroviruses and Opportunistic Infections. January 1996. Washington, DC, U.S.A.
170. Fiske W, Benedek Ich, Joseph JL. Pharmacokinetics of efavirenz and ritonavir after multiple oral doses in healthy volunteers (Abstract 42269). 12th World AIDS Conference. June 1998. Geneva, Switzerland.
171. Indinavir package insert by Merck, Sharpe & Dohme Company.
172. Ouellet D, Hsu A, Granneman GR, Carlson G, Cavanaugh J, Guenther H, Leonard JM. Pharmacokinetic interaction between ritonavir and clarithromycin. Clin Pharmacol Ther 1998; 64:355-62.
173. Ungo JR, Jones D, Ashkin D, Hollender ES, Bernstein D, Albanese AP, Pitchenik AE. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med 1998; 157:1871-6.
174. Centers for Disease Control and Prevention. Prevention and treatment of tuberculosis among patients with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR Morb Mortal Wkly Rep 1998; 47:1-58.
175. Vogel M, Voigt E, Michaelis HC, et al. Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected patients. Liver Transpl 2004; 10:939-44.
176. www.projinf.org/fs/drugin.html
177. Robertson SM, Penzak SR, Pau AK. Drug interactions in the management of HIV infection. Expert Opin Pharmacother 2005; 6:233-53.
178. Fellay J, Marzolini C, Greub G, Buclin T, Eap CB, Telenti, A. Predictive power of p-glycoprotein and CYP2D6 polymorphisms for plasma levels of antiretroviral agents. 8th CROI Chicago 2001; Abstracts 260.
179. Kim AY, Chung RT, Polsky B. Human immunodeficiency virus and hepatitis B and C coinfection:pathogenic interactions, natural history and therapy. AIDS Clin Rev 2000-2001:263-306.
180. Ockenga J, Tillmann HL, Trautwein C, Stoll M, Manns MP, Schmidt RE. Hepatitis B and C in HIVinfected patients. Prevalence and prognostic value. J Hepatol 1997; 27:18-24.
181. Dieterich DT. Hepatitis C virus and human immunodeficiency virus: clinical issues in coinfection. Am J Med 1999; 107:S79-84.
182. Diamondstone LS, Blakley SA, Rice JC, Clark RA, Goedert JJ. Prognostic factors for all cause mortality among hemophiliacs infected with human immunodeficiency virus. Am J Epidemiol 1995; 142:304-13.
183. Altfeld M, Rockstroh JK, Addo M, Kupfer B, Pult I, Will H, Spengler U. Reactivation of hepatitis B in a long-term anti-HBs-positive patient with AIDS following lamivudine withdrawal. J Hepatol 1998; 29:306-9.
184. Cooley L, Ayres A, Bartholomeusz A, et al. Prevalence and characterization of lamivudine-resistant hepatitis B virus mutations in HIV-HBV co-infected individuals. AIDS 2003; 17:1649-57.
185. Locarnini S, McMillan J, Bartholomeusz A. The hepatitis B virus and common mutants. Semin Liver Dis 2003; 23:5-20.
186. Carr A, Cooper DA. Restoration of immunity to chronic hepatitis B infection in an HIV-infected patient on protease inhibitor. Lancet 1997; 349:996-7.
187. Mastroianni CM, Trinchieri V, Santopadre P, et al. Acute clinical hepatitis in an HIV-positive hepatitis B carrier receiving protease inhibitor therapy. AIDS 1998; 112:1939-40.
188. Velasco M, Moran A, Tellez MJ. Resolution of chronic hepatitis B after ritonavir treatment in an HIVinfected patient. N Engl J Med 1999; 340:1765-6.
189. Castera L, Chouteau P, Hezode C, Zafrani ES, Dhumeaux D, Pawlotsky JM. Hepatitis C virusinduced hepatocellular steatosis. Am J Gastroenterol 2005; 100:711-5.
190. Barbaro G, Di Lorenzo G, Asti A, et al. Hepatocellular mitochondrial alterations in patients with chronic hepatitis C: ultrastructural and biochemical findings. Am J Gastroenterol 1999; 94:2198-205.
191. Okuda M, Li K, Beard MR, Showalter LA, Scholle F, Lemon SM, Winman SA. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002; 122:366-75.
192. Korenaga M, Wang T, Li Y, Showalter LA, Chan T, Sun J, Winman SA. Hepatitis C virus core protein inhibits mitochondrial electron transport and increases ROS production. J Biol Chem 2005; 280:37481-8.
193. Chou AH, Tsai HF, Wu YY, Hu CY, Hwang LH, Hsu PI, Hsu PN. Hepatitis C virus core protein modulates TRAIL-mediated apoptosis by enhancing Bid cleavage and activation of mitochondria apoptosis signaling pathway. J Immunol 2005; 174:2160-6.
194. Balasubramian A, Koziel M, Groopman JE, Ganju RK. Molecular mechanism of hepatic injury in coinfection with hepatitis C virus and HIV. Clin Infect Dis 2005; 41(Suppl. 1):S32-7.
195. Yamaguchi A, Tazuma S, Nishioka T, Ohishi W, Hyogo H, Momura S, Chayama K. Hepatitis C virus core protein modulates fatty acid metabolism and thereby causes lipid accumulation in the liver. Dig Dis Sci 2005; 50:1361-71.
196. Uberti-Foppa C, De Bona A, Morsica G, Galli L, Gallotta G, Boeri E, Lazzarin A. Pretreatment of chronic active hepatitis C in patients coinfected with HIV and hepatitis C virus reduces the hepatotoxicity associated with subsequent antiretroviral therapy. J Acquir Imm Defic Syndr 2003; 33:146-52.
197. John M, Flexman J, French MAH. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease? AIDS 1998; 12:2289-93.
198. Pérez-Olmeda M, García-Samaníego J, Soriano V. Hepatitis C viraemia in HIV-HCV co-infected patients having immune restoration with highly active antiretroviral therapy. AIDS 2000; 14:212.
199. Torti C, Lapadula G, Casari S, Puoti M, Nelson M, Quiros-Roldan E, Bella D, Pastore G, Ladisa N, Minoli L, et al. BMC Infect Dis 2005; 5:58.
200. Rutschmann OT, Negro F, Hirschel B, Hadengue A, Anwar D, Perrin LH. Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV. J Infect Dis 1998; 177:783-5.
201. Vento S, Garofano T, Renzini C. Enhancement of hepatitis C replication and liver damage in HIVconinfected patients on antiretroviral combination therapy. AIDS 1998; 12:116-7.
202. Chung RT, Evans SR, Yang Y, et al. Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects. AIDS 2002; 16:1915-23.
203. Núñez M, Ríos P, Martín-Carbonero L, Pérez-Olmeda M, González-Lahoz J, Soriano V. Role of hepatitis C virus genotype in the development of severe transaminase elevation after the introduction of antiretroviral therapy. J Acquir Imm Defic 2002; 30:65-8.
204. André P, Goettrup M, Klenerman P, et al. An inhibitor of HIV protease modulates proteasome activity, antigen presentation, and T cell responses. Proc Natl Acad Sci USA 1998; 95:12120-4.
205. Michelet C, Chapplain JM, Petsaris O, Arvieux C, Ruffault A, Lotteau V, André P. Differential effect of ritonavir and indinavir on immune responses to hepatitis C in HIV-1 infected patients. AIDS 1999; 13:1995-6.
206. Fialaire P, Payan C, Vitour D, Chennebault JM, Loison J, Pichard E, Lunel F. Sustained disappearance of hepatitis C viremia in patients receiving protease inhibitor treatment for HIV infection. J Infect Dis 1999; 180:574-5.
207. Zylberberg H, Chaix ML, Rabian C, et al. Tritherapy for human immunodeficiency virus infection does not modify replication of hepatitis C virus in coinfected subjects. Clin Infect Dis 1998; 26:1104-6.
208. Martín-Carbonero L, Núñez M, Ríos P, Pérez-Olmeda M, González-Lahoz J, Soriano V. Liver injury after beginning antiretroviral therapy in HIV/hepatitis C virus co-infected patients is not related to immune reconstitution. AIDS 2002; 16:1423-5.
209. Aranzabal L, Casado JL, Moya J, et al. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxcity in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 2005; 40:588-93.
210. Mauss S, Valenti W, De Pamphilis J, et al. Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy. AIDS 2004; 18:F21-5.
211. Cameron DW, Valdes J, Garber C. Ritonavir pharmacokinetics in HIV-infected patients with underlying hepatic disease (Abstract 359). 5th Conference on Retroviruses and Opportunistic Infections. February 1998. Chicago, U.S.A.
212. Tachikawa N, Yoshizawa S, Kikuchi Y, Yasuoka A, Oka S. Saquinavir therapy in patients with advanced HIV infection and liver cirrhosis. Jpn J Infect Dis 1999; 52:177.
213. Maserati R, Villani P, Seminari E, Pan A, Lo Caputo S, Regazzi MB. High plasma levels of nelfinavir and efavirenz in two HIV-positive patients with hepatic disease. AIDS 1999; 13:870-1.
214. González de Requena D, Núñez M, Jiménez-Nácher I, Soriano V. Liver toxicity caused by nevirapine. AIDS 2002; 16:290-1.
215. Lamson M, Maldonado S, Hutman H. The effects of underlying renal or hepatic dysfunction on the pharmacokinetics of nevirapine (Abstract TuPeB 3301). XIII International Conference on AIDS. July 2000. Durban, South Africa.
216. Agenerase (amprenavir) capsules and oral solution. Package insert, Research Triangle Park, NC, Glaxo Wellcome 1999.
217. Reyataz (atazanavir sulfate). Prescribing Information (U.S.A.). Princeton, NJ: Bristol Myers Squibb, 2003.
218. French AL, Benning L, Anastos K, Augenbraun M, Nowicki M, Sathasivam K, Terrault NA. Longitudinal effect of antiretroviral therapy on markers of hepatic toxicity: impact of hepatitis C coinfection. Clin Infect Dis 2004; 39:402-10.
219. Leitze Z, Nadeem A, Choudhary A, Saul Z, Roberts I, Manthous CA. Nevirapine-induced hepatitis treated with corticosteroids? AIDS 1998; 12:1115-7.